5 SEPTEMBER 2022 AT 8.00 EEST
Orion recalls Devisol Salmiakki dietary supplement from consumers
Orion is recalling all Devisol Salmiakki dietary supplement packages from consumers due to excessive levels of matrine in the product. Devisol Salmiakki has been on sale in Finland only starting from December 2021.
Consumers are requested to return both opened and unopened Devisol Salmiakki products to the nearest pharmacy at the latest on 13 October 2022. The products will be reimbursed for the consumers. Empty packages or free samples will not be reimbursed. The recall does not concern Orion’s other Devisol products.
The recall is due to levels of matrine in the licorice extract used in the Devisol Salmiakki product which have been found to exceed the maximum level allowed by the EU. Matrine occurs naturally in certain plants and is also used as a pesticide. Regarding matrine, there is no EU-level risk assessment and approval, and there is therefore no certainty about the safety of foodstuffs containing it. As a precaution, all batches of Devisol Salmiakki on the market are withdrawn. The daily recommended dose of Devisol Salmiakki is one tablet, in which case the exposure to matrine through this preparation is assumed to be low. Orion has not received any reports of adverse effects related to the Devisol Salmiakki product, and Orion is not aware of any consumer reports related to the safety of the Devisol Salmiakki product.
The recall has no material financial impact on Orion.
Orion apologises for the inconvenience that returning the product causes for our customers.
Product information and customer service: tel. +358 10 439 8250
Media contact: Terhi Ormio, Vice President, Communications, tel. +358 50 966 4646
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are oncology and pain. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.